Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) and Dr. Reddy’s Laboratories (NYSE:RDY – Get Free Report) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.
Earnings & Valuation
This table compares Tvardi Therapeutics and Dr. Reddy’s Laboratories”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tvardi Therapeutics | $7.14 million | 2.50 | -$18.21 million | ($2.79) | -0.48 |
| Dr. Reddy’s Laboratories | $3.58 billion | 3.45 | $456.00 million | $0.37 | 40.04 |
Dr. Reddy’s Laboratories has higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than Dr. Reddy’s Laboratories, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and price targets for Tvardi Therapeutics and Dr. Reddy’s Laboratories, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tvardi Therapeutics | 1 | 0 | 6 | 1 | 2.88 |
| Dr. Reddy’s Laboratories | 1 | 3 | 2 | 0 | 2.17 |
Tvardi Therapeutics presently has a consensus price target of $9.40, indicating a potential upside of 601.49%. Dr. Reddy’s Laboratories has a consensus price target of $492.90, indicating a potential upside of 3,227.03%. Given Dr. Reddy’s Laboratories’ higher probable upside, analysts plainly believe Dr. Reddy’s Laboratories is more favorable than Tvardi Therapeutics.
Profitability
This table compares Tvardi Therapeutics and Dr. Reddy’s Laboratories’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tvardi Therapeutics | N/A | -145.40% | -91.11% |
| Dr. Reddy’s Laboratories | 8.56% | 7.91% | 5.29% |
Risk and Volatility
Tvardi Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Dr. Reddy’s Laboratories has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
Institutional & Insider Ownership
44.7% of Tvardi Therapeutics shares are held by institutional investors. Comparatively, 3.8% of Dr. Reddy’s Laboratories shares are held by institutional investors. 7.4% of Tvardi Therapeutics shares are held by company insiders. Comparatively, 2.0% of Dr. Reddy’s Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Summary
Dr. Reddy’s Laboratories beats Tvardi Therapeutics on 8 of the 14 factors compared between the two stocks.
About Tvardi Therapeutics
Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases involving abnormal STAT3 signaling. STAT3 is a protein that can contribute to tumor growth, treatment resistance and immune suppression, making it a potential target for drug development. The company’s lead investigational product is TTI-101, an orally administered small-molecule inhibitor designed to block STAT3 activity. Tvardi is evaluating TTI-101 in clinical studies for solid tumors, including hepatocellular carcinoma and other advanced cancers.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based pharmaceutical company that develops, manufactures and markets generic medicines, active pharmaceutical ingredients (APIs) and other healthcare products. Its portfolio includes branded and unbranded generics, biosimilars and select proprietary medicines across therapeutic areas such as oncology, gastroenterology, cardiovascular care and diabetes. Founded in 1984 by Kallam Anji Reddy, the company is headquartered in Hyderabad, India. It serves patients and customers in India and international markets, including the United States, Europe and countries in Russia and the Commonwealth of Independent States.
Receive News & Ratings for Tvardi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tvardi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
